Sage Therapeutics (NASDAQ:SAGE) Given “Neutral” Rating at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE) in a research note released on Thursday, Benzinga reports. HC Wainwright currently has a $25.00 price target on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Citigroup started coverage on shares of Sage Therapeutics in a research note on Wednesday, May 29th. They set a sell rating and a $8.00 price objective on the stock. Mizuho cut their price objective on shares of Sage Therapeutics from $18.00 to $16.00 and set a neutral rating on the stock in a report on Friday, July 19th. Royal Bank of Canada decreased their price objective on shares of Sage Therapeutics from $26.00 to $15.00 and set a sector perform rating for the company in a research report on Friday, April 26th. JPMorgan Chase & Co. lowered Sage Therapeutics from an overweight rating to a neutral rating and dropped their target price for the stock from $18.00 to $12.00 in a research report on Thursday. Finally, Canaccord Genuity Group reduced their price target on Sage Therapeutics from $21.00 to $17.00 and set a hold rating for the company in a report on Friday, April 26th. Two research analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Sage Therapeutics presently has a consensus rating of Hold and an average price target of $33.55.

Sage Therapeutics Trading Up 5.0 %

SAGE stock opened at $10.99 on Thursday. Sage Therapeutics has a 12-month low of $9.73 and a 12-month high of $37.17. The company has a market cap of $661.40 million, a PE ratio of -1.31 and a beta of 0.90. The stock has a 50-day moving average price of $11.28 and a two-hundred day moving average price of $16.76.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The business had revenue of $7.90 million for the quarter, compared to analyst estimates of $5.26 million. During the same quarter in the previous year, the firm posted ($2.46) EPS. The business’s revenue was up 139.4% compared to the same quarter last year. Equities analysts forecast that Sage Therapeutics will post -6.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Lazard Asset Management LLC acquired a new stake in Sage Therapeutics in the first quarter worth $127,000. China Universal Asset Management Co. Ltd. grew its position in shares of Sage Therapeutics by 353.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,937 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 5,406 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Sage Therapeutics in the 2nd quarter worth about $177,000. Virtu Financial LLC acquired a new stake in shares of Sage Therapeutics in the 1st quarter worth about $187,000. Finally, ProShare Advisors LLC lifted its position in Sage Therapeutics by 9.0% in the 1st quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock valued at $257,000 after purchasing an additional 1,130 shares during the last quarter. Institutional investors and hedge funds own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.